Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
A Phase I Study of Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Sponsor: Pfizer
Terminated
Due to departure of PI from St. Jude
A PHASE1 clinical study on Acute Lymphoblastic Leukemia With Failed Remission and Acute Lymphoblastic Leukemia, in Relapse, this trial is terminated or withdrawn. The trial is conducted by Pfizer and has accumulated 11 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Aug 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 6 earlier versions
-
Nov 2019 — Aug 2020 [monthly]
Recruiting PHASE1
-
Jul 2019 — Nov 2019 [monthly]
Recruiting PHASE1
-
May 2019 — Jul 2019 [monthly]
Recruiting PHASE1
-
Dec 2018 — May 2019 [monthly]
Recruiting PHASE1
-
Jul 2018 — Dec 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
First recorded
Apr 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
- St. Jude Children's Research Hospital
For direct contact, visit the study record on ClinicalTrials.gov .